Home Cart Sign in  
Chemical Structure| 2549174-42-5 Chemical Structure| 2549174-42-5

Structure of Lirafugratinib
CAS No.: 2549174-42-5

Chemical Structure| 2549174-42-5

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

Lirafugratinib is an orally active inhibitor targeting FGFR2. It inhibits tumor cell growth by suppressing FGFR2 activity and shows therapeutic potential for tumors with FGFR2 mutations or amplifications.

Synonyms: RLY-4008

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of Lirafugratinib

CAS No. :2549174-42-5
Formula : C28H24FN7O2
M.W : 509.53
SMILES Code : C=C(C)C(NC1=CC=C(C2=C(C3=CC=C(OC4=NC=CC(C)=N4)C(F)=C3)C5=C(N)N=CN=C5N2C)C=C1)=O
Synonyms :
RLY-4008
MDL No. :N/A

Safety of Lirafugratinib

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319
Precautionary Statements:P501-P270-P264-P280-P302+P352-P337+P313-P305+P351+P338-P362+P364-P332+P313-P301+P312+P330

Related Pathways of Lirafugratinib

RTK
JAK-STAT

Isoform Comparison

Biological Activity

Target
  • FGFR2

Clinical Trial:

NCT Number Conditions Phases Recruitment Completion Date Locations
NCT04526106 FGFR2 Amplification|FGFR2 Gene... More >> Mutation|FGFR2 Gene Fusion/Rearrangement|FGFR2 Gene Translocation|FGFR2 Gene Activation|Intrahepatic Cholangiocarcinoma|Cholangiocarcinoma|Other Solid Tumors, Adult Less << PHASE1|PHASE2 ACTIVE_NOT_RECRUITING 2025-12-27 The University of Alabama at B... More >>irmingham, Birmingham, Alabama, 35294, United States|Mayo Clinic, Phoenix, Arizona, 85054, United States|USC Norris Comprehensive Cancer Center, Los Angeles, California, 90033, United States|UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, California, 94158, United States|Mayo Clinic, Jacksonville, Florida, 32224, United States|Moffitt Cancer Center, Tampa, Florida, 33612, United States|Winship Cancer Institute, Emory University, Atlanta, Georgia, 30322, United States|University of Chicago Medical Center, Chicago, Illinois, 60637, United States|Massachusetts General Hospital, Boston, Massachusetts, 02114, United States|University of Michigan, Ann Arbor, Michigan, 48109, United States|Mayo Clinic, Rochester, Minnesota, 55905, United States|Memorial Sloan Kettering Cancer Center, New York, New York, 10065, United States|Taussig Cancer Institute Cleveland Clinic, Cleveland, Ohio, 44195, United States|Fox Chase Cancer Center, Philadelphia, Pennsylvania, 19111, United States|Texas Oncology, Dallas, Texas, 75246, United States|The University of Texas M.D. Anderson Cancer Center, Houston, Texas, 77030, United States|Huntsman Cancer Institute, University of Utah, Salt Lake City, Utah, 84112, United States|Virginia Mason Medical Center, Seattle, Washington, 98101, United States|St. Vincent's Hosptial Sydney, Darlinghurst, 2010, Australia|Linear Clinical Research Ltd, Nedlands, 6009, Australia|Icon Cancer Care South Brisbane, South Brisbane,, 4101, Australia|Institut Bergonie, Bordeaux, 33076, France|Centre Georges Fran?ois Leclerc, Dijon, 21079, France|Centre Leon Berard, Lyon, 69373, France|Gustave Roussy Cancer Campus, Paris, 94805, France|Medizinische Hochschule Hannover, Hannover, 30625, Germany|Universit?tsklinikum Heidelberg, Heidelberg, 69120, Germany|LMU Klinikum, Campus Grosshadern, Munich, 81377, Germany|Queen Mary Hospital, Hong Kong, 999077, Hong Kong|Istituto Europeo di Oncologia, Milano, 20141, Italy|Seoul National University Hospital, Seoul, 03080, Korea, Republic of|Asan Medical Center, Seoul, 05505, Korea, Republic of|Samsung Medical Center, Seoul, 06351, Korea, Republic of|Netherlands Cancer institute, Amsterdam, 1066 CX, Netherlands|Erasmus MC, Rotterdam, 3015 GD, Netherlands|National Cancer Center Singapore, Singapore, 169610, Singapore|START Barcelona-Hospital HM Nou Delfos, Barcelona, 08023, Spain|Hospital Universitari Vall d'Hebron, Barcelona, 08035, Spain|Hospital Universitario Fundación Jiménez Díaz- START MADRID, Madrid, 28040, Spain|Hospital Universitario HM Sanchinarro-START MADRID-CIOCC, Madrid, 28050, Spain|Clinica de Universidad de Navarra, Pamplona, 31008, Spain|Hospital Clínico Universitario de Valencia, Valencia, 46010, Spain|Karolinska University Hospital, Stockholm, 17176, Sweden|China Medical University Hospital, Taichung, 40447, Taiwan|Guy's Hospital, London, SE1 9RT, United Kingdom|Sarah Cannon Research Institute UK, London, W1G 6AD, United Kingdom|University College London Hospitals NHS Foundation Trust, London, W1T 7HA, United Kingdom|The Christie NHS Foundation Trust, Manchester, M20 4BX, United Kingdom Less <<

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

1.96mL

0.39mL

0.20mL

9.81mL

1.96mL

0.98mL

19.63mL

3.93mL

1.96mL

References

 

Historical Records

Categories